MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...

Related Keywords

Planegg ,Bayern ,Germany ,University Hospital ,Florida ,United States ,Massachusetts ,Orlando ,Delaware ,Boston ,Canada ,American ,Tim Demuth ,Johannes Duell ,Steven Stein ,Practice Research Clinical Haematology ,Twitter ,American Association For Cancer Research Annual Meeting ,Linkedin ,Exchange Commission ,Distribution Services ,Nasdaq ,Morphosys Us Inc ,Xencor Inc ,American Association For Cancer Research ,Drug Administration ,Incyte Announce Five Year Results ,Showed Prolonged ,Durable Responses ,American Association ,Cancer Research Annual Meeting ,Cancer Research ,Annual Meeting ,Medical Clinic ,Chief Research ,Development Officer ,Chief Medical Officer ,Diffuse Largeb Cell Lymphoma ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Morphosy Annual Report ,Practice Research ,Corporate News ,Regulatory Announcements ,